Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV 2018;5(8):e438-e47. https://www.ncbi.nlm.nih.gov/pubmed/30025681
Bisson GP, Molefi M, Bellamy S, Thakur R, Steenhoff A, Tamuhla N, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis.[Erratum appears in Clin Infect Dis. 2013 Oct;57(7):1067]. Clin Infect Dis 2013;56(8):1165-73. https://www.ncbi.nlm.nih.gov/pubmed/23362285
Chow EP, Read TR, Chen MY, Fehler G, Bradshaw CS, Fairley CK. Routine CD4 cell count monitoring seldom contributes to clinical decision-making on antiretroviral therapy in virologically suppressed HIV-infected patients. HIV Med 2015;16(3):196-200. https://www.ncbi.nlm.nih.gov/pubmed/25236189
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375(9):830-9. https://www.ncbi.nlm.nih.gov/pubmed/27424812
Croxford S, Stengaard AR, Brannstrom J, Combs L, Dedes N, Girardi E, et al. Late diagnosis of HIV: An updated consensus definition. HIV Med 2022;23(11):1202-8. https://www.ncbi.nlm.nih.gov/pubmed/36347523
Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. Clin Infect Dis 2018;66(suppl_2):S152-S9. https://www.ncbi.nlm.nih.gov/pubmed/29514236
Gale HB, Gitterman SR, Hoffman HJ, Gordin FM, Benator DA, Labriola AM, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/muL and HIV-1 suppression? Clin Infect Dis 2013;56(9):1340-3. https://www.ncbi.nlm.nih.gov/pubmed/23315315
Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA 2023;329(1):63-84. https://www.ncbi.nlm.nih.gov/pubmed/36454551
Girard PM, Nelson M, Mohammed P, Hill A, van Delft Y, Moecklinghoff C. Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment? AIDS 2013;27(17):2759-63. https://www.ncbi.nlm.nih.gov/pubmed/23842127
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.[Erratum appears in Lancet Infect Dis. 2014 Apr;14(4):269]. Lancet Infect Dis 2014;14(4):281-90. https://www.ncbi.nlm.nih.gov/pubmed/24602844/
HIV in Europe. HIV Indicator Conditions: Guidance for Implementing HIV Testing in Adults in Health Care Settings. Copenhagen; 2012.
Insight Start Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373(9):795-807. https://www.ncbi.nlm.nih.gov/pubmed/26192873
Lin YD, Eades L, Nair A, Korman TM, Woolley I. Review of HIV testing recommendations in Australian specialty guidelines for HIV indicator conditions: a missed opportunity for recommending testing? Intern Med J 2019;50(3):293-8. https://www.ncbi.nlm.nih.gov/pubmed/31566841
Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018;391(10123):839-49. https://www.ncbi.nlm.nih.gov/pubmed/29310899
McKenney J, Bauman S, Neary B, Detels R, French A, Margolick J, et al. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012. Clin Infect Dis 2015;60(6):959-65. https://www.ncbi.nlm.nih.gov/pubmed/25422390
Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 2015;385(9983):2173-82. https://www.ncbi.nlm.nih.gov/pubmed/25765698
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, D.C.: Department of Health and Human Services (USA); 2023. Updated March 2023. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suarez-Lozano I, Riera M, et al. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother 2017;72(1):246-53. https://www.ncbi.nlm.nih.gov/pubmed/27629070
Pulido F, Ribera E, Lagarde M, Perez-Valero I, Palacios R, Iribarren JA, et al. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clin Infect Dis 2017;65(12):2112-8. https://www.ncbi.nlm.nih.gov/pubmed/29020293
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy.[Erratum appears in JAMA. 2016 Aug 9;316(6):667; PMID: 27532931], [Erratum appears in JAMA. 2016 Nov 15;316(19):2048; PMID: 27838699]. JAMA 2016;316(2):171-81. https://www.ncbi.nlm.nih.gov/pubmed/27404185
Tang Z, Lan G, Chen YQ, Zhu Q, Yang X, Shen Z, et al. HIV-1 treatment-as-prevention: A cohort study analysis of serodiscordant couples in rural southwest China. Medicine 2015;94(24):e902. https://www.ncbi.nlm.nih.gov/pubmed/26091454
Waters L, Winston A, Reeves I, Boffito M, Churchill D, Cromarty B, et al. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. HIV Med 2022;23 Suppl 5:3-115. https://www.ncbi.nlm.nih.gov/pubmed/36504313
World Health Organization (WHO). Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children (Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection). Geneva: WHO; 2018.
https://www.who.int/publications/i/item/9789241550277
